Pan-neurodegeneration proteomics reveals disease subtypes and molecular signatures
Summary
Neurodegenerative diseases (NDs) pose clinical challenges due to their complexity and molecular heterogeneity. Here, we present a pan-neurodegeneration atlas (PanNDA) from multilayer, deep proteomic analysis of 2,279 human brain samples spanning 6 major NDs: Alzheimer's disease (AD), Lewy body dementia (LBD), frontotemporal lobar degeneration with TDP-43 pathology, progressive supranuclear palsy with tau pathology, vascular dementia, and Parkinson's disease. PanNDA integrates data from who
Content
# Pan-neurodegeneration proteomics reveals disease subtypes and molecular signatures
*Published: 2026 May 14*
Neurodegenerative diseases (NDs) pose clinical challenges due to their
complexity and molecular heterogeneity. Here, we present a pan-neurodegeneration
atlas (PanNDA) from multilayer, deep proteomic analysis of 2,279 human brain
samples spanning 6 major NDs: Alzheimer's disease (AD), Lewy body dementia
(LBD), frontotemporal lobar degeneration with TDP-43 pathology, progressive
supranuclear palsy with tau pathology, vascular dementia, and Parkinson's
disease. PanNDA integrates data from whole proteome, detergent-insoluble
proteome, and posttranslational modifications (phosphorylation and
ubiquitination), enabling intra- and inter-disease comparisons. Intra-disease
analyses uncover distinct molecular subtypes (e.g., three in AD and four in
LBD), reveal dysregulated pathways, and prioritize top-ranked proteins.
Inter-disease comparisons identify shared alterations in NDs, such as GPNMB in
microglial and lysosomal activation and NPTX2 in synaptic regulation, alongside
disease-specific changes and hub regulators within protein networks. Overall,
PanNDA provides a systems-level framework for understanding ND mechanisms and
serves as a foundational resource that is accessible via an interactive website:
https://penglab.shinyapps.io/pannda.
DOI: 10.1016/j.cell.2026.02.026